UNIVERSIDADE FEDERAL DO RIO DE JANEIRO ... - UFRJ

XIV- REFERÊNCIAS CONSULTADAS1. ALBERTI, I., KALIA, Y.N., NAIK, A., BONNY, J-D., GUY, R.H. In vivoassessment of enhanced topical delivery of terbinafine to human stratumcorneum. Journal Controlled Release, 71: 319-327, 2001.2. ANSEL, H. C.; ALLEN Jr, L. V.; POPOVICH, N. G. Pharmaceutical dosageforms and drug delivery systems, 7 th Ed, Lippincott Williams and Wilkins, p.548-551, 1999.3. FDA/CDER-GTDDP Guidance for industry: topical dermatological drugproducts NDAs and ANDAs – in vivo bioavailability, bioequivalence, in vitrorelease and associated studies [online]. DEPARTMENT OF. HEALTH ANDHUMAN SERVICES FDA/CDER. Disponível: http://www.fda.gov/cder/guindace/index.htm [6/2/1998].4. LILLIE, T. H.; SCHRECK, C. E.; RAHE, A. J. Effectiveness of personalprotection against mosquitoes in Alaska 1988. Journal of MedicalEntomology, 25: 475, 1988.5. MINISTÉRIO DA SAÚDE - FUNASA - Programas e Projetos de Saúde[online]. Disponível: http:/www.funasa.gov.br/epi/dengue.htm#. Rio deJaneiro.6. QIU, H.; JUN, H. W.; McCALL, J. W. Pharmacokinetics, formulation, andsafety of insect repellent N, N-diethyl-3-methylbenzamide (deet): a review.Journal of American Mosquito Control Association, 14: 12-27, 1998.7. RIVIERE, E.J. Biological factors in absorption and permeation. In: ZATZ,J.L., Skin permeation fundamentals and application. Ed. Joel L. Zatz.Estados Unidos: Allured Publishing Corp. Wheaton II, cap.5, p.113-125,1993.8. SHAH, V.P.; FLYNN, G.L.; YACOBI, A.; MAIBACH, H.I.; BON, C.;FLEISCHER, N.M.; FRANZ, T.J.; KAPLAN, S.A.; KAWAMOTO, J.; LESKO,L.J.; MARTY, J.P.; PERSHING, L.K.; SCHAEFER, H.; SEQUEIRA, J.A.;SHRIVASTAVA, S.P.; WILKIN, J.; WILLIAMS, R.L. Bioequivalence oftopicaldermatological dosage forms – methods of evaluation ofbioequivalence. Pharmaceutical Research, 15: 167-171, 1998.9. YOUNG, D.LTC G.; EVANS, S. Safety and efficacy of DEET and permethrinin the prevention of arthropod attack. Military Medicine, 163: 324-330, 1998.19